secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dare Bioscience, Inc. (DARE)
CIK:        0001401914
Form:       8-K
Filed at:   2024-11-14T23:59:59+00:00
Accession:  0001493152-24-045860
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Daré Bioscience Q3 2024: cash $11.2M; grants up to $10.7M and $10M; pipeline advancing
--------------------------------------------------------------------------------

- Cash and equivalents $11.2M at Sept 30, 2024; R&D expenses fell 60% YoY to $2.7M; G&A $2.0M.
- Foundation grant of up to ~$10.7M for novel non-hormonal contraceptive and to add Ovaprene Phase 3 sites.
- ARPA-H award of $10M for DARE-HPV IND-enabling activities; NICHD grant of $2M for DARE-PTB1.
- Ovaprene Phase 3 enrolling at 10 US sites; target ~125 women completing 6 mo by Q2 2025.
- Sildenafil Cream Phase 3 discussions with FDA ongoing; each Phase 3 study est. ~$15M direct costs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401914/000149315224045860/0001493152-24-045860-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401914/000149315224045860/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-045860

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer